October 2014 Blog Posts (8)

Companion Diagnostics: Paying a Central Role in the Success of Personalized Medicine

There has been a real revolution in the understanding of molecular biology. This revolution is fueled by the rapid decline in the costs of sequencing, which allowed next-generation sequencing (NGS) assays, previously only seen in research laboratories, to begin making inroads into molecular diagnostics. The wide-ranging capabilities of next-generation sequencing offer extraordinary opportunities for the development and new companion diagnostics to probe oncogenes, tumor suppressor genes…

Continue

Added by Editorial Team on October 29, 2014 at 11:30am — No Comments

Increased Risk of Heart-Related Deaths in Men with Cardiovascular Problems Linked to Prostate Cancer Medications

A new study first published online in the October 29, 2014 issue of BJU International, has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. According to the authors, the findings will help doctors and patients weigh the benefits and risks of these drugs.

Androgen deprivation therapy or ADT, which is designed to reduces levels of male hormones in the…

Continue

Added by Editorial Team on October 29, 2014 at 11:00am — No Comments

Study Identifies Genetic Variant that Protects some Latina Women from Breast Cancer - Reducing Risk by 40 to 80 Percent

A group of international researchers led by scientists at UC San Francisco, the nation's leading university exclusively focused on health, have identified a genetic variant common in Latina women that protects against breast cancer.

The variant, a difference in just one of the three billion "letters" in the human genome known as a single-nucleotide polymorphism or SNP, originates from indigenous Americans and confers significant protection from breast cancer. The…

Continue

Added by Editorial Team on October 20, 2014 at 7:30am — No Comments

Development of Intestinal Organoids form Mature Human Tissue in Mice Produces Unprecedented Model to Study Intestinal Diseases

Scientists at the Cincinnati Children's Hospital Medical Center in collaboration with researchers at the Department of Internal Medicine, University of Michigan, have successfully transplanted "organoids" of functioning human intestinal tissue grown from pluripotent stem cells in a lab dish into mice – creating an unprecedented model for studying diseases of the intestine.[1]

Reporting their results in the…

Continue

Added by Editorial Team on October 19, 2014 at 4:00pm — No Comments

Researchers find Disruptions of the Biological Clock Increase Breast Cancer Risk

Research by scientists at University of Georgia shows that the disruption of the circadian rhythm or -- our '24-hour biological clock' -- has been linked to an increased risk of breast cancer. In this study the culprit is artificial light.[1]

"Exposure to artificial light leads to a significantly higher risk for developing breast cancer," explained Chunla He, a biostatistics graduate student in the UGA College of Public Health. "To decrease the use of artificial light, people…

Continue

Added by Editorial Team on October 17, 2014 at 10:00pm — No Comments

Initial Phase I Trial Results of anti-EGFR drug ABT-414 in the Treatment of Patients with Glioblastoma Multiforme

With a median survival between 1 and 2 years and no long-term curative treatments, the management of patients with Glioblastoma Multiforme (GBM), the most common and most aggressive type of malignant primary brain tumor, remains challenging. Prior to initial diagnosis, most patients experience a serious symptom, such as a seizure. Standard treatment is surgical resection,…

Continue

Added by Editorial Team on October 16, 2014 at 5:00pm — No Comments

Pharmacyclics and Roche Agree to Jointly Evaluate Ibrutinib and Obinutuzumab in Lymphoma and Leukemia

Pharmacyclics, Inc and Roche earlier today announced that the two companies have entered into a master clinical drug supply agreement designed to evaluate the safety, tolerability and preliminary efficacy of ibrutinib (Imbruvica®; Pharmacyclics), an oral Bruton's tyrosine kinase (BTK) inhibitor, in combination with obinutuzumab (Gazyva®; Genentech/Roche), a new CD20-directed antibody that attacks targeted cells both directly and together with the body's immune system, in patients with…

Continue

Added by Editorial Team on October 16, 2014 at 3:00pm — No Comments

TRIBECA Study Supports Potential for Bioequivalence Between Cynviloq and Albumin-Bound Paclitaxel

Recently analyzed pharmacokinetic (PK) data from the first eight (8) patients enrolled in Sorrento Therapeutics' ongoing TRIBECA™ Study (TRIal establishing BE between Cynviloq™ and Albumin-bound paclitaxel) registrational trial shows positive results. Cynviloq, also known as IG-001 or Genexol-PM, is a novel nanoparticle formulation of paclitaxel.[1]

IG-001 and albumin-bound paclitaxel (…

Continue

Added by Editorial Team on October 14, 2014 at 7:30pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+